2007-11-07

Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye


Sydney, November 7 (ots/PRNewswire) - In the Lancet, on TuesdayNovember, 6th new results of the Fenofibrate Intervention and EventLowering in Diabetes (FIELD) 2007 clinical trial have been publishedand presented on the same date at a press conference held during theAHA.

- First lipid modifying agent shown to reduce the need fortreatment of the leading causes of blindness and deteriorating visionin patients with type 2 diabetes

- Reduces need for laser treatment in patients with and withoutknown diabetic retinopathy

- Significantly decreases progression of diabetic eye disease

If you are interested in knowing more about this breaking news andin getting additional information on the management of microvascularcomplications in type 2 diabetes, we are pleased to invite you tovisit "the Field Study Investigators Website", where you will havethe opportunity to login to the Webcast of the press conference.

Please click below: http://www.thefieldtrial.org

ots Originaltext: NHMRC Clinical Trials Centre - The University of SydneyIm Internet recherchierbar: http://www.presseportal.de

Contact:Media Contact: Beth Quinlivan, University of Sydney, Ph: +61-2-9036-6528, Mob: +61-0-419-229-134, bquinlivan@med.usyd.edu.au

NHMRC Clinical Trials Centre - The University of Sydney

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

Medizin-News